Neovacs (ALNEV.PA) Stock Price
Neovacs Price
Over the last 17 years Neovacs grew revenue by 4.9% annually, reaching 291,300.00 EUR. For Neovacs, the net margin of -11,299.1% is up versus -20,613.1% a few years ago.
Neovacs stock price
Neovacs business model & stock analysis
Frequently asked questions about Neovacs
9 analysts currently rate the Neovacs stock: 8 recommend buying, 1 holding and 0 selling.
The revenue cannot currently be calculated for Neovacs.
The profit cannot currently be calculated for Neovacs.
The P/E ratio cannot be calculated for Neovacs at the moment.
The P/S cannot be calculated for Neovacs currently.
The Eulerpool Quality Score for Neovacs is 4/10.
The ISIN of Neovacs is FR0014010856. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Neovacs is A1CVKR. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Neovacs is ALNEV.PA. The ticker symbol is used to trade Neovacs shares on the stock exchange.
Neovacs stock
All fundamentals and in-depth analysis of Neovacs
Our stock analysis for Neovacs stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neovacs. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.